A Multicenter, Randomized, Open-Label, Dose Ranging Study to Evaluate the Efficacy and Safety of Patiromer in the Treatment of Hyperkalemia in Patients With Hypertension and Diabetic Nephropathy Receiving Angiotensin-converting Enzyme Inhibitor (ACEI) and/or Angiotensin II Receptor Blocker (ARB) Drugs, With or Without Spironolactone.

Trial Profile

A Multicenter, Randomized, Open-Label, Dose Ranging Study to Evaluate the Efficacy and Safety of Patiromer in the Treatment of Hyperkalemia in Patients With Hypertension and Diabetic Nephropathy Receiving Angiotensin-converting Enzyme Inhibitor (ACEI) and/or Angiotensin II Receptor Blocker (ARB) Drugs, With or Without Spironolactone.

Completed
Phase of Trial: Phase II

Latest Information Update: 11 Apr 2018

At a glance

  • Drugs Patiromer (Primary)
  • Indications Hyperkalaemia
  • Focus Therapeutic Use
  • Acronyms AMETHYST-DN
  • Sponsors Relypsa
  • Most Recent Events

    • 11 Apr 2018 According to the Relypsa media release, findings from pooled analysis from this and other two trials (OPAL-HK and TOURMALINE) will be presented in a poster session at the National Kidney Foundation's (NKF) 2018 Spring Clinical Meetings (SCM18).
    • 11 Apr 2018 Results from pooled analysis of this and other two trials (OPAL-HK and TOURMALINE) presented in the Relypsa media release.
    • 30 Aug 2017 Results (n=653) of pooled post hoc analysis assessing effect of patiromer on serum K+ in patients with HK and HF using data from AMETHYST-DN, OPAL-HK and TOURMALINE trials presented at the ESC Congress 2017: Annual Congress of the European Society of Cardiology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top